Peer-review started: May 7, 2015
First decision: August 11, 2015
Revised: November 23, 2015
Accepted: December 17, 2015
Article in press: December 18, 2015
Published online: January 8, 2016
Processing time: 252 Days and 13.7 Hours
Metabonomics has recently been widely used to discover the pathogenesis and find potential metabolic markers with high sensitivity and specificity. Furthermore, it develops new diagnosis and treatment methods, increases early phase diagnosis rates of certain diseases and provides a new basis for targeted therapy. This review mainly analyzes the research progress of the metabonomics of hepatitis B virus (HBV)-related hepatic diseases, hoping to discover some potential metabolic markers for identification of HBV-related hepatic diseases from other etiologies and for HBV-related hepatitis, liver cirrhosis and hepatocellular carcinoma. This can contribute to early discovery, diagnosis and treatment, eventually increasing the survival rate of HBV-related hepatic diseases.
Core tip: This review mainly analyzes the research progress of the metabonomics of hepatitis B virus (HBV)-related hepatic diseases, hoping to discover some potential metabolic markers which can distinguish HBV-related hepatic diseases from other etiologies and discover potential metabolic markers of HBV-related hepatitis, liver cirrhosis and hepatocellular carcinoma, which can contribute to early discovery, diagnosis and treatment.